Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2013 by Xinghua Tan, Guangzhou 8th People's Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Xinghua Tan, Guangzhou 8th People's Hospital Identifier:
First received: October 24, 2013
Last updated: October 31, 2013
Last verified: October 2013
To meet eligibility criteria, this study and informed consent of the syndrome of fever associated with bleeding of infectious diseases, severe patients to carry out multicenter, practical randomized controlled clinical research, to compare the curative effect of western medicine, combining Chinese and western medicine treatment, and security, and pathogenesis of TCM and syndrome, severe immune related factor and syndrome type of traditional Chinese medicine, Chinese medicine prescriptions mechanism research.

Condition Intervention Phase
Viral Haemorrhagic Fever
Dengue Fever
Drug: Western Medicine
Drug: TCM and Western Medicine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research

Resource links provided by NLM:

Further study details as provided by Xinghua Tan, Guangzhou 8th People's Hospital:

Primary Outcome Measures:
  • Mortality [ Time Frame: Anytime of the clinical trail from 2011.1.1 to 2015.12.30 ]

Secondary Outcome Measures:
  • Safety outcome [ Time Frame: From 2012.1 to 2015.12 ]
    With adverse events as the calculation basis

Estimated Enrollment: 300
Study Start Date: January 2012
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TCM and Western Medicine
TCM and Western Medicine:First Infectious diseases soup recipe,every time a dose,Two times a day;Ribavirin 10-15mg per kg every time Western Medicine:Ribavirin 10-15mg per kg every time
Drug: Western Medicine
Physical cooling,Hydrocortisone
Other Name: Ribavirin,
Drug: TCM and Western Medicine
Third Infectious diseases soup recipe
Other Name: Second Infectious diseases soup recipe and Ribavirin
Placebo Comparator: Western Medicine
Western Medicine:Ribavirin 10-15mg per kg every time
Drug: TCM and Western Medicine
Third Infectious diseases soup recipe
Other Name: Second Infectious diseases soup recipe and Ribavirin

Detailed Description:
Randomized method: using large sample, central randomized, parallel comparison of Chinese and western medicine and western medicine group.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Viral diseases, such as dengue fever, kidney of hemorrhagic fever, such as xinjiang hemorrhagic fever; Or clinical has fever associated with bleeding as the main performance, and confirmed as the new emergent infectious diseases

Exclusion Criteria:

  • Diagnosed with flu, hand, foot and mouth disease, viral hepatitis (except the carrier), liver cirrhosis after hepatitis, AIDS, rabies, encephalitis, polio, measles, German measles, chickenpox, herpes, infectious mononucleosis, infectious atypical pneumonia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01973855

Contact: Tan X Hua 13500039656

China, Shanxi
Xi 'an eighth people's hospital Recruiting
XiAn, Shanxi, China, 710000
Contact: Xu R Fang    13008415052   
Sponsors and Collaborators
Guangzhou 8th People's Hospital
Study Director: Tan X Hua Guangzhou 8th hospitol
  More Information

Responsible Party: Xinghua Tan, Director of Department of infection area, Guangzhou 8th People's Hospital Identifier: NCT01973855     History of Changes
Other Study ID Numbers: 2012ZX10004301-003
Study First Received: October 24, 2013
Last Updated: October 31, 2013

Additional relevant MeSH terms:
Hemorrhagic Fevers, Viral
Body Temperature Changes
Signs and Symptoms
Arbovirus Infections
Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents processed this record on May 25, 2017